Non-small cell lung cancer in South Wales: Are Exon 19 deletions and L858R different?

Davies, R. S., Nelms, D. J., Butler, Rachel and Lester, J. F. 2016. Non-small cell lung cancer in South Wales: Are Exon 19 deletions and L858R different? Anticancer Research 36 (8) , pp. 4267-4271.

Full text not available from this repository.

Abstract

Background/Aim: In advanced non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) mutations L858R and exon 19 deletion (del19) predict response to EGFR tyrosine kinase inhibitors (TKIs). Trials have suggested a differential response to the second-generation EGFR TKI afatinib in favour of del19. We investigated whether this differential response is observed in clinical practice. Materials and Methods: Retrospective demographic, treatment and outcome data were collected on patients with: stage III/IV NSCLC and either del19 or L858R, receiving an EGFR TKI as first-line treatment. Results: There was no significant difference in overall survival (OS) between del19 (648 days, 95% confidence interval (CI)=461-835) and L858R (813 days, 95%CI=387-1,238), (p=0.616), or in duration of therapy between del19 (365 days, 95% CI=192-538) and L858 (428 days, 95% CI=263-593), (p=0.928). Conclusion: Patients with exon del19 did not have a significantly longer OS with first-generation TKIs.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Uncontrolled Keywords:	EGFR mutation, exon 19 deletion, L858R, advanced non-small cell lung cancer, NSCLC
Publisher:	International Institute of Anticancer Research
ISSN:	0250-7005
Date of Acceptance:	1 July 2016
Last Modified:	20 Nov 2019 15:41
URI:	https://orca.cardiff.ac.uk/id/eprint/103988

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item